Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants.
about
Efficient sample preparation in immuno-matrix-assisted laser desorption/ionization mass spectrometry using acoustic trapping.Transthyretin variants with improved inhibition of β-amyloid aggregation.Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetesDelineation of concentration ranges and longitudinal changes of human plasma protein variants.Mass spectrometry-based protein assays for in vitro diagnostic testing.Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma.Quantitative mass spectrometric immunoassay for the chemokine RANTES and its variants.Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoformsMass spectrometric immunoassays for discovery, screening and quantification of clinically relevant proteoforms.Assuring Consistent Performance of an Insulin-Like Growth Factor 1 MALDImmunoassay by Monitoring Measurement Quality IndicatorsTotal ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptidesMass Spectrometric Immunoassays in Characterization of Clinically Significant Proteoforms.Sample preparation strategies for targeted proteomics via proteotypic peptides in human blood using liquid chromatography tandem mass spectrometry.Human proteoforms as new targets for clinical mass spectrometry protein tests.Advantageous uses of mass spectrometry for the quantification of proteins.Development of quantitative mass spectrometric immunoassay for serum amyloid A.Shotgun-proteomics-based clinical testing for diagnosis and classification of amyloidosis.Mass Spectrometric Studies of Apolipoprotein Proteoforms and Their Role in Lipid Metabolism and Type 2 Diabetes.
P2860
Q30441133-3196995E-3B45-4009-A91C-CAF4DB44D62BQ30757280-E4845929-14D9-4A71-8EF0-5B3E0C028F70Q33643266-F0A73304-D30D-4272-BDB2-ECBDD9A747F9Q33793513-4AEAD190-6D1B-43F6-9E7D-06CFD22AA252Q34216869-2F6227FC-659D-4A90-9BFA-A236DA59C335Q34644418-5697998A-CE75-400B-9CFD-CC172C571D2AQ35166976-B640287D-15DF-4EC1-B844-E71DAE5A7440Q36072219-2BAC3D18-4712-4A2D-B2C7-595D21220A78Q36072250-815536CF-878D-4FBF-ACDF-CFEE093996D9Q36361741-73DDC926-FEAF-494C-820B-1088CB9E5307Q36386913-08E1AD9B-C96F-46CC-9F38-9A89FF336384Q37566426-33E92EDF-53AC-472C-AB59-58F69AFE2BF8Q38270732-4536418A-35BD-4439-B771-154A82E71BA8Q38649742-4BAC9E58-DA53-4ECA-BFE0-411217C941A8Q41773275-DF1E026E-AAE1-4C0D-852C-14ED24E0A6A5Q46155938-B07DBDBB-2B83-443F-84C1-71C1044228EFQ46432012-3BFA0895-5E63-464C-9CD9-50E0542C217DQ47163663-2A1A2A1D-93A4-44E8-A4D1-7275849E5BB0
P2860
Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Mass spectrometric immunoassay ...... ransthyretin and its variants.
@ast
Mass spectrometric immunoassay ...... ransthyretin and its variants.
@en
type
label
Mass spectrometric immunoassay ...... ransthyretin and its variants.
@ast
Mass spectrometric immunoassay ...... ransthyretin and its variants.
@en
prefLabel
Mass spectrometric immunoassay ...... ransthyretin and its variants.
@ast
Mass spectrometric immunoassay ...... ransthyretin and its variants.
@en
P2093
P2860
P356
P1433
P1476
Mass spectrometric immunoassay ...... ransthyretin and its variants.
@en
P2093
Dobrin Nedelkov
Elena Kamcheva
Olgica Trenchevska
P2860
P304
P356
10.1002/PMIC.201100023
P577
2011-08-09T00:00:00Z